PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Chou R, Dana T, Bougatsos C, et al. Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 May. (Evidence Syntheses, No. 110.)

References

1.
U.S. Preventive Services Task Force. Screening for Hepatitis B Virus Infection. 2004. www​.uspreventiveservicestaskforce​.org/uspstf/uspshepb.htm.
2.
Research Triangle Institute-University of North Carolina. Screening for Hepatitis B Virus Infection: A Brief Evidence Update for the U.S. Preventive Services Task Force. 2004. www​.uspreventiveservicestaskforce​.org/3rduspstf​/hepbscr/hepbup.pdf.
3.
Lin K, Vickery J. Screening for hepatitis B virus infection in pregnant women: evidence for the United States Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2009;150(12):874–6. [PubMed: 19528566]
4.
United States Preventive Services Task Force. Screening for hepatitis B virus infection in pregnancy. Ann Intern Med. 2009;150:869–73. [PubMed: 19528565]
5.
Lin KW, Kirchner JT. Hepatitis B. Am Fam Physician. 2004;69(1):75–82. [PubMed: 14727820]
6.
Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR. 2006;55(RR-16):1–33. quiz CE1-4. [PubMed: 17159833]
7.
Centers for Disease Control and Prevention. Interpretation of Hepatitis B Serologic Test Results. 2005. [14 May 2014]. www​.cdc.gov/hepatitis​/hbv/pdfs/serologicchartv8.pdf.
8.
Dusheiko G, Antonakopoulos N. Current treatment of hepatitis B. Gut. 2008;57(1):105–24. [PubMed: 17502343]
9.
Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1–31. [PubMed: 16371945]
10.
Centers for Disease Control and Prevention. Viral Hepatitis Statistics and Surveillance: Disease Burden from Viral Hepatitis A, B, and C in the United States. 2013. [14 May 2014]. www​.cdc.gov/hepatitis/Statistics/index​.htm.
11.
Centers for Disease Control and Prevention. Viral Hepatitis Surveillance—United States, 2010. [14 May 2014]. www​.cdc.gov/hepatitis​/Statistics/2010Surveillance/
12.
Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med. 2011;154(5):319–28. [PubMed: 21357909]
13.
Centers for Disease Control and Prevention. Viral Hepatitis Statistics & Surveillance: Table 3.5 Number and rate of deaths with hepatitis B listed as a cause of death, by demographic characteristic and year — United States, 2006–2010. 2013. www​.cdc.gov/hepatitis​/Statistics/2011Surveillance/Table3​.5.htm.
14.
Centers for Disease Control and Prevention. Hepatitis B General Fact Sheet. 2010. www​.cdc.gov/hepatitis​/hbv/pdfs/hepbgeneralfactsheet.pdf.
15.
Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR. 2008;57(RR-8):1–20. [PubMed: 18802412]
16.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52. [PubMed: 18096267]
17.
Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73. [PubMed: 16391218]
18.
Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–86. [PubMed: 16530509]
19.
Kowdley KV, Wang CC, Welch S, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012;56(2):422–33. [PubMed: 22105832]
20.
Mitchell T, Armstrong GL, Hu DJ, et al. The increasing burden of imported chronic hepatitis B—United States, 1974–2008. PLoS ONE. 2011;6(12):e27717. [PMC free article: PMC3233539] [PubMed: 22163270]
21.
Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B. Ann Intern Med. 2009;150:104–10. [PubMed: 19124811]
22.
Quaglio G, Lugoboni F, Mezzelani P, et al. Hepatitis vaccination among drug users. Vaccine. 2006;24(15):2702–9. [PubMed: 16436307]
23.
Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis—United States, 2006. MMWR Surveill Summ. 2008;57(2):1–24. [PubMed: 18354374]
24.
World Health Organization. WHO Vaccine Preventable Diseases Monitoring System. 2013. http://www​.who.int/immunization​/monitoring_surveillance​/burden/VPDs/en/
25.
Centers for Disease C Prevention. Implementation of newborn hepatitis B vaccination—worldwide, 2006. MMWR. 2008;57(46):1249–52. [PubMed: 19023261]
26.
Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26(49):6266–73. [PubMed: 18848855]
27.
Lok AS, McMahon BJ. American Association for the Study of Liver Diseases (AASLD) Practice Guideline Update: Chronic Hepatitis B: Update 2009. Hepatology. 2009;50:661. [PubMed: 19714720]
28.
Keeffe EB, Dieterich DT, Han SHB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6(12):1315–41. [PubMed: 18845489]
29.
Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45(4):1056–75. [PubMed: 17393513]
30.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507–39. [PubMed: 17256718]
31.
Institute of Medicine. Report Brief January 2010: Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. 2010. www​.iom.edu/Reports/2010​/Hepatitis-and-Liver-Cancer-A-National-Strategy-for-Prevention-and-Control-of-Hepatitis-B-and-C​.aspx/ [PubMed: 25032367]
32.
Harris RP, Helfand M, Wolff SH, et al. Current methods of the United States Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3S):21–35. [PubMed: 11306229]
33.
U.S. Preventive Services Task Force. Procedure Manual. 2008. AHRQ Publication No. 08-05118. www​.uspreventiveservicestaskforce​.org/uspstf08​/methods/procmanual.htm.
34.
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557–60. [PMC free article: PMC192859] [PubMed: 12958120]
35.
Spenatto N, Boulinguez S, Mularczyk M, et al. Hepatitis B screening: who to target? A French sexually transmitted infection clinic experience. J Hepatol. 2013;58(4):690–7. [PubMed: 23220369]
36.
Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database Syst Rev. 2005;(4):CD000100. [PubMed: 16235273]
37.
Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303(15):833–41. [PubMed: 6997738]
38.
Coutinho RA, Lelie N, Albrecht-Van Lent P, et al. Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br Med J Clin Res Ed. 1983;286(6374):1305–8. [PMC free article: PMC1547658] [PubMed: 6404440]
39.
Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med. 1982;97(3):362–6. [PubMed: 6810736]
40.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348(9):800–7. [PubMed: 12606734]
41.
Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology. 2008;47(6):1863–71. [PubMed: 18433023]
42.
Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808–16. [PubMed: 12606735]
43.
Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006;44(1):108–16. [PubMed: 16799983]
44.
Bayraktar Y, Uzunalimoglu B, Arslan S, et al. Effects of recombinant alpha interferon on chronic active hepatitis B: preliminary results. Gut. 1993;34(2 Suppl):S101. [PMC free article: PMC1374024] [PubMed: 8314468]
45.
Hadziyannis S, Bramou T, Makris A, et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol. 1990;11(Suppl 1):S133–6. [PubMed: 2079571]
46.
Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997;26(6):1621–5. [PubMed: 9398007]
47.
Muller R, Baumgarten R, Markus R, et al. Treatment of chronic hepatitis B with interferon alfa-2b. J Hepatol. 1990;11(1):S137–40. [PubMed: 2079572]
48.
Perez V, Tanno H, Villamil F, et al. Recombinant interferon alfa-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J Hepatol. 1990;11(Suppl 1):S113–7. [PubMed: 2079567]
49.
Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990;323(5):295–301. [PubMed: 2195346]
50.
Sarin SK, Guptan RC, Thakur V, et al. Efficacy of low-dose alpha interferon therapy in HBV-related chronic liver disease in Asian Indians: a randomized controlled trial. J Hepatol. 1996;24(4):391–6. [PubMed: 8738724]
51.
Waked I, Amin M, Abd el Fattah S, et al. Experience with interferon in chronic hepatitis B in Egypt. J Chemother. 1990;2(5):310–8. [PubMed: 2090770]
52.
Ali HY. Trial of lamivudine in hepatitis B surface antigen carriers with persistent hepatitis B core IgM antibody. Saudi Med J. 2003;24(9):996–9. [PubMed: 12973486]
53.
Bozkaya H, Yurdaydin C, Idilman R, et al. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia. Antivir Ther. 2005;10(2):319–25. [PubMed: 15865226]
54.
Chan HLY, Wang H, Niu J, et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007;12(3):345–53. [PubMed: 17591024]
55.
Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341(17):1256–63. [PubMed: 10528035]
56.
Lai CL, Ching CK, Tung AK, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 1997;25(1):241–4. [PubMed: 8985298]
57.
Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339(2):61–8. [PubMed: 9654535]
58.
Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999;29(3):889–96. [PubMed: 10051494]
59.
Yalcin K, Degertekin H, Kokoglu OF, et al. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels. Turk J Gastroenterol. 2004;15(1):14–20. [PubMed: 15264116]
60.
Yao G, Wang B, Cui Z, et al. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin Med J. 1999;112(5):387–91. [PubMed: 11593504]
61.
Murray KF, Szenborn L, Wysocki J, et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology. 2012;56(6):2018–26. [PubMed: 22544804]
62.
Lai CL, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004;40(3):719–26. [PubMed: 15349912]
63.
Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 2010;52(6):2192–205. [PubMed: 20890947]
64.
Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001–10. [PubMed: 16525137]
65.
Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133(5):1437–44. [PubMed: 17983800]
66.
Chang TT, Chao YC, Gorbakov VV, et al. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2009;16(11):784–9. [PubMed: 19457141]
67.
Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011–20. [PubMed: 16525138]
68.
Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002;123(6):1831–8. [PubMed: 12454840]
69.
Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol. 2007;13(31):4264–7. [PMC free article: PMC4250629] [PubMed: 17696259]
70.
Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–95. [PubMed: 15987917]
71.
Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206–17. [PubMed: 15371578]
72.
Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442–55. [PubMed: 19052126]
73.
Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29(3):971–5. [PubMed: 10051505]
74.
Liaw YF, Lin SM, Chen TJ, et al. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. J Hepatol. 1994;20(2):175–80. [PubMed: 8006397]
75.
Mazzella G, Saracco G, Festi D, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol. 1999;94(8):2246–50. [PubMed: 10445557]
76.
Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–31. [PubMed: 15470215]
77.
Yu HB, Liu EQ, Lu SM, et al. Treatment with peginterferon versus interferon in Chinese patients with hepatitis B. Biomed Pharmacother. 2010;64(8):559–64. [PubMed: 20630699]
78.
Yao GB. Management of hepatitis B in China. J Med Virol. 2000;61(3):392–7. [PubMed: 10861652]
79.
Yao GB, Zhu M, Cui ZY, et al. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009;10(2):131–7. [PubMed: 19426396]
80.
Andreone P, Gramenzi A, Cursaro C, et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat. 2004;11(5):439–42. [PubMed: 15357649]
81.
Baltayiannis G, Katsanos K, Karayiannis P, et al. Interferon-α therapy in HBeAg-negative chronic hepatitis B: a long-term prospective study from north-western Greece. Aliment Pharmacol Ther. 2006;24(3):525–33. [PubMed: 16886919]
82.
Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40(4):883–91. [PubMed: 15382125]
83.
Fattovich G, Giustina G, Realdi G, et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP) Hepatology. 1997;26(5):1338–42. [PubMed: 9362381]
84.
Hui CK, Leung N, Shek WH, et al. Changes in liver histology as a “surrogate” end point of antiviral therapy for chronic HBV can predict progression to liver complications. J Clin Gastroenterol. 2008;42(5):533–8. [PubMed: 18344885]
85.
Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003;37(4):756–63. [PubMed: 12668967]
86.
Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334(22):1422–7. [PubMed: 8618580]
87.
Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001;34(2):306–13. [PubMed: 11281561]
88.
Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut. 2011;60(8):1109–16. [PubMed: 21270118]
89.
Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997;113(5):1660–7. [PubMed: 9352870]
90.
Shamliyan TA, Johnson JR, MacDonald R, et al. Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med. 2011;26(3):326–39. [PMC free article: PMC3043173] [PubMed: 21203860]
91.
Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol. 2009;44(5):470–5. [PubMed: 19308310]
92.
Zhang QQ, An X, Liu YH, et al. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J. 2011;8:72. [PMC free article: PMC3046930] [PubMed: 21324130]
93.
Lai CL, Yuen MF. Prevention of hepatitis b virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57(1):399–408. [PubMed: 22806323]
94.
Wong GLH, Yiu KKL, Wong VWS, et al. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2010;32(9):1059–68. [PubMed: 20807216]
95.
Jin H, Pan N, Mou Y, et al. Long-term effect of interferon treatment on the progression of chronic hepatitis B: bayesian meta-analysis and meta-regression. Hepatol Res. 2011;(41):512–23. [PubMed: 21501353]
96.
Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53(2):348–56. [PubMed: 20483498]
97.
Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139(4):1218–29. [PubMed: 20600036]
98.
Liang J, Tang YF, Wu FS, et al. Entecavir versus lamivudine for the treatment of chronic hepatitis B: a systematic review. Pharmazie. 2012;67(11):883–90. [PubMed: 23210236]
99.
Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health. 2010;13(8):934–45. [PubMed: 20825624]
100.
Zhao SH, Liu EQ, Cheng DX, et al. Comparison of entecavir and adefovir for the treatment of chronic hepatitis B. Braz J Infect Dis. 2012;16(4):366–72. [PubMed: 22846126]
101.
Chou R, Hartung D, Rahman B, et al. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med. 2013;158:114–23. [PubMed: 23437439]
102.
Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336(26):1855–9. [PubMed: 9197213]
103.
Lim SG, Mohammed R, Yuen MF, et al. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol. 2009;24(8):1352–7. [PubMed: 19702903]
104.
Morrison A, Polisena J, Husereau D, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care. 2012;28(02):138–44. [PubMed: 22559755]
105.
Pham B, Klassen TP, Lawson ML, et al. Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary. J Clin Epidemiol. 2005;58(8):769–76. [PubMed: 16086467]
106.
Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinom-a. J Cancer Res Clin Oncol. 2004;130(7):417–22. [PubMed: 15042359]
107.
Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10(4):204–9. [PubMed: 14738659]
108.
Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveill Summ. 2009. www​.cdc.gov/mmwr/pdf/ss/ss5803.pdf.
109.
Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202(2):192–201. [PubMed: 20533878]
110.
Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9. [PubMed: 22273662]
111.
Cox N, Tillmann H. Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs. 2011;16(4):713–29. [PubMed: 22195605]
112.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2. [PubMed: 19714720]
113.
Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8(5):275–84. [PubMed: 21423260]
114.
Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int. 2011;5(2):644–53. [PMC free article: PMC3090558] [PubMed: 21484123]
115.
Centers for Disease Control and Prevention. Screening for chronic hepatitis B among Asian/Pacific Islander populations—New York City, 2005. MMWR. 2006;55(18):505–9. [PubMed: 16691180]
116.
Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology. 2007;46(4):1034–40. [PubMed: 17654490]
117.
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. [PMC free article: PMC3200068] [PubMed: 21767103]
118.
Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med. 2007;147(1):58–61. [PubMed: 17606962]
Cover of Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults
Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation [Internet].
Evidence Syntheses, No. 110.
Chou R, Dana T, Bougatsos C, et al.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...